Célèste Lebbé
Hôpital Saint-Louis
4 papers in the Anchorcite directory, published between 2010 and 2017, cited 31,095 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 4 papers
- Cutaneous Melanoma Detection and Management · 4 papers
- Melanoma and MAPK Pathways · 3 papers
- Immunotherapy and Immune Responses · 1 paper
Frequent co-authors
- Caroline Robert · 3 papers
- Dirk Schadendorf · 3 papers
- Jedd D. Wolchok · 3 papers
- Michele Maio · 3 papers
- Frank Stephen Hodi · 2 papers
- Steven J O'Day · 2 papers
- Jeffrey Alan Sosman · 2 papers
- John B.A.G. Haanen · 2 papers
Papers
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine · 2010 · 15,401 citations
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100)…
- Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine · 2011 · 4,600 citations
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study…
Metadata from OpenAlex (CC0).